



May 14, 2015

## **VIVUS Announces Scientific Presentations**

MOUNTAIN VIEW, CA -- (Marketwired) -- 05/14/15 -- VIVUS, Inc. (NASDAQ: VVUS), a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health, today announced the following scientific presentations:

### **Conference**

***AACE 2015: American Association of Clinical Endocrinologists***

***24<sup>th</sup> Annual Scientific and Clinical Congress***

May 13-17, 2015

Music City Convention Center, Nashville, TN

### **Date/Time**

**Poster Presentation Date:** Friday, May 15, 2015, 9:45am - 11:00am and 12:30pm - 2:00pm CT

**Session Location:** Exhibit Hall, Hall B, Third Floor of the Music City Convention Center.

**Poster Number:** 614

### **Presentation Title**

Second Prospective, Pharmacoepidemiologic Database Analysis of Qsymia<sup>®</sup> (Phentermine and Topiramate Extended-Release) Usage From a Representative US Sample of Patients

**Authors:** Craig A. Peterson, MS; Xanna Steelman, BA; Santosh T. Varghese, MD

**Affiliations:** VIVUS, Inc. , Mountain View, CA

### **Conference**

***ISPOR 2015: International Society for Pharmacoeconomics and Outcomes Research***

***20th Annual International Meeting***

May 16-20, 2015

Philadelphia Marriott Downtown, Philadelphia, PA

### **Date/Time**

**Poster Presentation Date:** Wednesday, May 20, 2015, 8:30am - 2:45pm ET

**Poster Author Discussion Hour:** 12:45pm - 1:45pm ET

**Session Location:** Level 4 Franklin Hall, Philadelphia Marriott Hotel

**Poster Number:** PSY13

### **Presentation Title:**

Second Prospective, Pharmacoepidemiologic Database Analysis of Phentermine and Topiramate Extended-Release Usage From a Representative US Sample of Older Patients

**Authors:** Craig A. Peterson, MS; Xanna Steelman, BA; Santosh T. Varghese, MD

**Affiliations:** VIVUS, Inc. , Mountain View, CA

### **Date/Time**

**Poster Presentation Date:** Wednesday, May 20, 2015 at 8:30AM - 2:45PM

**Poster Author Discussion Hour:** 12:45pm - 1:45pm ET

**Session Location:** Level 4 Franklin Hall, Philadelphia Marriott Hotel

**Poster Number:** PSY32

### **Presentation Title:**

Effect of Weight Loss on Concomitant Medication Costs in Individuals with Metabolic Syndrome Receiving Phentermine/Topiramate Extended-Release

**Authors:** Scott Kahan, MD, MPH<sup>a</sup>; Sunil Karnawat, PhD<sup>b</sup>

**Affiliations:** <sup>a</sup>George Washington University, Washington, DC; <sup>b</sup>VIVUS, Inc., Mountain View, CA

### **About VIVUS**

VIVUS is a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. For more information about the company, please visit [www.vivus.com](http://www.vivus.com).

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely," "may," "plan," "potential," "predict," "opportunity" and "should," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS's Form 10-K for the year ended December 31, 2014 as filed on February 25, 2015 and as amended by the Form 10-K/A filed on April 30, 2015, and periodic reports filed with the Securities and Exchange Commission. VIVUS does not undertake an obligation to update or revise any forward-looking statements.

CONTACT :

VIVUS, Inc.  
Dana B Shinbaum  
Corporate Development & Investor Relations  
[shinbaum@vivus.com](mailto:shinbaum@vivus.com)

Investor Relations:  
The Trout Group  
Brian Korb  
[bkorb@troutgroup.com](mailto:bkorb@troutgroup.com)  
646-378-2923

Source: VIVUS, Inc.

News Provided by Acquire Media